Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr 29.
doi: 10.1097/FTD.0000000000001338. Online ahead of print.

Ceftobiprole in Critically Ill Patients: Proposal for New Dosage Regimens

Sarah Baklouti  1   2 , Camille Mané  1 , Youssef Bennis  3 , Charles-Edouard Luyt  4 , Cédric Joseph  5 , Stéphanie Ruiz  6 , Romain Guilhaumou  7 , Didier Concordet  2 , Noël Zahr  8 , Peggy Gandia  1   2
Affiliations

Ceftobiprole in Critically Ill Patients: Proposal for New Dosage Regimens

Sarah Baklouti et al. Ther Drug Monit. .

Abstract

Background: Ceftobiprole is a broad-spectrum cephalosporin. It is currently approved for the treatment of community- and hospital-acquired pneumonia. However, the recommended dosage regimen of ceftobiprole may not be sufficient to achieve the optimal pharmacokinetic/pharmacodynamic criterion in critically ill patients. The study aimed to evaluate whether the dosage regimens proposed by the manufacturers ensure that the optimal pharmacokinetic/pharmacodynamic criterion is achieved in over 90% of critically ill patients.

Methods: Ceftobiprole concentrations were measured in 27 patients admitted to intensive care unit. An external evaluation of published population pharmacokinetic models was performed using simulations. The model that best described the data was used to evaluate the dosage regimens proposed for intensive care unit patients by evaluating the probability of attaining the optimal pharmacokinetic/pharmacodynamic criterion (100% fT > 4 * minimum inhibitory concentration). In addition, the same model was used to suggest dosage regimen adjustments for these patients.

Results: Of the 4 models evaluated, Muller's population pharmacokinetic model was selected as the best for describing the concentrations observed in 27 patients. Simulations performed with this model have shown that the manufacturer's dosing regimens do not achieve the optimal pharmacokinetic/pharmacodynamic criterion in critically ill patients. Consequently, adaptation of dosing regimens to ensure ceftobiprole effectiveness in at least 90% of the patients was proposed.

Conclusions: The proposed dosing regimens can be used to guide ceftobiprole administration in critically ill patients. However, measurement of ceftobiprole plasma concentration remains essential, at least once, to confirm patient exposure.

Keywords: ceftobiprole; critically ill patients; pharmacodynamic; population pharmacokinetics; therapeutic drug monitoring.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Nicholson SC, Welte T, File TM, et al. A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisation. Int J Antimicrob Agents. 2012;39:240–246.
    1. Awad SS, Rodriguez AH, Chuang YC, et al. A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia. Clin Infect Dis. 2014;59:51–61.
    1. Holland TL, Cosgrove SE, Doernberg SB, et al. Ceftobiprole for treatment of complicated Staphylococcus aureus bacteremia. N Engl J Med. 2023;389:1390–1401.
    1. Guilhaumou R, Benaboud S, Bennis Y, et al. Optimization of the treatment with beta-lactam antibiotics in critically ill patients-guidelines from the French Society of Pharmacology and Therapeutics (Société Française de Pharmacologie et Thérapeutique-SFPT) and the French Society of Anaesthesia and Intensive Care Medicine (Société Française d'Anesthésie et Réanimation-SFAR). Crit Care. 2019;23:104.
    1. Lodise TP, Patel N, Renaud-Mutart A, et al. Pharmacokinetic and pharmacodynamic profile of ceftobiprole. Diag Microbiol Infect Dis. 2008;61:96–102.

LinkOut - more resources